Your browser doesn't support javascript.
loading
Losartan treatment enhances chemotherapy efficacy and reduces ascites in ovarian cancer models by normalizing the tumor stroma.
Zhao, Yanxia; Cao, Jinghong; Melamed, Alexander; Worley, Michael; Gockley, Allison; Jones, Dennis; Nia, Hadi T; Zhang, Yanling; Stylianopoulos, Triantafyllos; Kumar, Ashwin S; Mpekris, Fotios; Datta, Meenal; Sun, Yao; Wu, Limeng; Gao, Xing; Yeku, Oladapo; Del Carmen, Marcela G; Spriggs, David R; Jain, Rakesh K; Xu, Lei.
Afiliação
  • Zhao Y; Edwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114.
  • Cao J; Edwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114.
  • Melamed A; Gynecologic Cancers Program, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114.
  • Worley M; Division of Gynecologic Oncology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02130.
  • Gockley A; Division of Gynecologic Oncology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02130.
  • Jones D; Division of Gynecologic Oncology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02130.
  • Nia HT; Edwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114.
  • Zhang Y; Edwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114.
  • Stylianopoulos T; Edwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114.
  • Kumar AS; Cancer Biophysics Laboratory, Department of Mechanical and Manufacturing Engineering, University of Cyprus, 1678 Nicosia, Cyprus.
  • Mpekris F; Edwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114.
  • Datta M; Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, MA 02139.
  • Sun Y; Cancer Biophysics Laboratory, Department of Mechanical and Manufacturing Engineering, University of Cyprus, 1678 Nicosia, Cyprus.
  • Wu L; Edwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114.
  • Gao X; Edwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114.
  • Yeku O; Edwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114.
  • Del Carmen MG; Edwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114.
  • Spriggs DR; Gynecologic Cancers Program, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114.
  • Jain RK; Division of Gynecologic Oncology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02130.
  • Xu L; Gynecologic Cancers Program, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114.
Proc Natl Acad Sci U S A ; 116(6): 2210-2219, 2019 02 05.
Article em En | MEDLINE | ID: mdl-30659155
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Ascite / Células Estromais / Losartan / Antineoplásicos Tipo de estudo: Prognostic_studies Limite: Animals / Female / Humans Idioma: En Ano de publicação: 2019 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Ascite / Células Estromais / Losartan / Antineoplásicos Tipo de estudo: Prognostic_studies Limite: Animals / Female / Humans Idioma: En Ano de publicação: 2019 Tipo de documento: Article